National Liver Health Initiative

Aligned with the strategic goals of "Healthy China 2030," Hotgen Biotech has established a comprehensive, full-lifecycle liver health management platform covering the entire spectrum from hepatitis to liver cancer, and from diagnosis to treatment. The platform’s diagnostic and early-screening portfolio includes the Liver Cancer Three Items (AFP, AFP-L3%, and DCP), the Fatty Liver Two Items (CK18-M30/M65), Golgi Protein 73 (GP73), the Liver Fibrosis Panel (five markers), Glycocholic Acid (CG), Hepatitis B Virus Large Surface Protein (HBV-LP), ctDNA methylation assays, and exosome-based testing. For disease risk prediction, we offer the C-GALAD AI-powered liver cancer risk assessment model. Medication guidance includes the HBV RNA and Metabolic-Related Fatty Liver Multi-gene Detection PCR Kit. Therapeutic options include antibody-based drugs and live bacterial therapeutics. Complemented by public welfare initiatives such as the "Healthy China Liver Cancer Prevention Campaign" and the popular science education IP "Gan Xiaoxin," this comprehensive initiative is dedicated to safeguarding liver health throughout the entire lifespan of the Chinese population.